Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Breast Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
HER2 Negative Breast Cancer (415
)
HER2 Positive Breast Cancer (402
)
Hormone Receptor Positive Breast Cancer (308
)
Triple Negative Breast Cancer (299
)
Estrogen Receptor Positive Breast Cancer (204
)
Male Breast Cancer (9
)
Hormone Receptor Negative Breast Cancer (3
)
HER2 Negative Breast Cancer (415
)
HER2 Positive Breast Cancer (402
)
Hormone Receptor Positive Breast Cancer (308
)
Triple Negative Breast Cancer (299
)
Estrogen Receptor Positive Breast Cancer (204
)
Male Breast Cancer (9
)
Hormone Receptor Negative Breast Cancer (3
)
›
Associations
(2006)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
ER mutation
HER2 Negative Breast Cancer
ER mutation
HER2 Negative Breast Cancer
elacestrant
Sensitive: A1 - Approval
FDA - 4 days (New A1)
elacestrant
Sensitive
:
A1
FDA - 4d
elacestrant
Sensitive: A1 - Approval
FDA - 4 days
elacestrant
Sensitive
:
A1
FDA - 4 days - (New A1)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
dasatinib + lapatinib
Sensitive: D – Preclinical
PLoS One - 4 days (New D)
dasatinib + lapatinib
Sensitive
:
D
PLoS One - 4d
dasatinib + lapatinib
Sensitive: D – Preclinical
PLoS One - 4 days
dasatinib + lapatinib
Sensitive
:
D
PLoS One - 4 days - (New D)
HER-2 underexpression
Breast Cancer
HER-2 underexpression
Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
Daiichi Sankyo Press Release - 5 days (New A1)
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
Daiichi Sankyo Press Release - 5d
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
Daiichi Sankyo Press Release - 5 days
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
Daiichi Sankyo Press Release - 5 days - (New A1)
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
CDK6 inhibitor
Sensitive: B - Late Trials
Endokrynol Pol - 1 week (New C3)
CDK6 inhibitor
Sensitive
:
B
Endokrynol Pol - 1wk
CDK6 inhibitor
Sensitive: B - Late Trials
Endokrynol Pol - 1 week
CDK6 inhibitor
Sensitive
:
B
Endokrynol Pol - 1 week - (New C3)
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
CDK4 inhibitor
Sensitive: B - Late Trials
Endokrynol Pol - 1 week (New C3)
CDK4 inhibitor
Sensitive
:
B
Endokrynol Pol - 1wk
CDK4 inhibitor
Sensitive: B - Late Trials
Endokrynol Pol - 1 week
CDK4 inhibitor
Sensitive
:
B
Endokrynol Pol - 1 week - (New C3)
RET fusion + TP53 mutation
HER2 Positive Breast Cancer
RET fusion + TP53 mutation
HER2 Positive Breast Cancer
pyrotinib
Resistant: C4 – Case Studies
Anticancer Drugs - 1 week (New C4)
pyrotinib
Resistant
:
C4
Anticancer Drugs - 1wk
pyrotinib
Resistant: C4 – Case Studies
Anticancer Drugs - 1 week
pyrotinib
Resistant
:
C4
Anticancer Drugs - 1 week - (New C4)
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
CFI-402257
Sensitive: B - Late Trials
Treadwell Therap Press Release - 3 weeks (New B)
CFI-402257
Sensitive
:
B
Treadwell Therap Press Release - 3wk
CFI-402257
Sensitive: B - Late Trials
Treadwell Therap Press Release - 3 weeks
CFI-402257
Sensitive
:
B
Treadwell Therap Press Release - 3 weeks - (New B)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A1 - Approval
Breast Cancer - 3 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
A1
Breast Cancer - 3wk
trastuzumab + pertuzumab
Sensitive: A1 - Approval
Breast Cancer - 3 weeks
trastuzumab + pertuzumab
Sensitive
:
A1
Breast Cancer - 3 weeks - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A1 - Approval
Ther Adv Med Oncol - 3 weeks (New C3)
trastuzumab
Sensitive
:
A1
Ther Adv Med Oncol - 3wk
trastuzumab
Sensitive: A1 - Approval
Ther Adv Med Oncol - 3 weeks
trastuzumab
Sensitive
:
A1
Ther Adv Med Oncol - 3 weeks - (New C3)
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
alpelisib
Sensitive: A1 - Approval
Oncogene - 3 weeks (New C3)
alpelisib
Sensitive
:
A1
Oncogene - 3wk
alpelisib
Sensitive: A1 - Approval
Oncogene - 3 weeks
alpelisib
Sensitive
:
A1
Oncogene - 3 weeks - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
lapatinib
Sensitive: A2 - Guideline
Eur J Cancer - 3 weeks (New B)
lapatinib
Sensitive
:
A2
Eur J Cancer - 3wk
lapatinib
Sensitive: A2 - Guideline
Eur J Cancer - 3 weeks
lapatinib
Sensitive
:
A2
Eur J Cancer - 3 weeks - (New B)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
pyrotinib
Sensitive: B - Late Trials
PLoS One - 3 weeks (New C3)
pyrotinib
Sensitive
:
B
PLoS One - 3wk
pyrotinib
Sensitive: B - Late Trials
PLoS One - 3 weeks
pyrotinib
Sensitive
:
B
PLoS One - 3 weeks - (New C3)
PD-L1 expression
Triple Negative Breast Cancer
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
trastuzumab + tucatinib
Sensitive
:
A1
trastuzumab + tucatinib
Sensitive: A1 - Approval
trastuzumab + tucatinib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
margetuximab
Sensitive: A1 - Approval
margetuximab
Sensitive
:
A1
margetuximab
Sensitive: A1 - Approval
margetuximab
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
No biomarker
Breast Cancer
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A1 - Approval
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A1
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A1 - Approval
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: A1 - Approval
ado-trastuzumab emtansine
Sensitive
:
A1
ado-trastuzumab emtansine
Sensitive: A1 - Approval
ado-trastuzumab emtansine
Sensitive
:
A1
No biomarker
Breast Cancer
No biomarker
Breast Cancer
TAC
Sensitive: A1 - Approval
TAC
Sensitive
:
A1
TAC
Sensitive: A1 - Approval
TAC
Sensitive
:
A1
HR positive
HER2 Positive Breast Cancer
HR positive
HER2 Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
neratinib
Sensitive
:
A1
neratinib
Sensitive: A1 - Approval
neratinib
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
palbociclib
Sensitive: A1 - Approval
palbociclib
Sensitive
:
A1
palbociclib
Sensitive: A1 - Approval
palbociclib
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
ribociclib
Sensitive: A1 - Approval
ribociclib
Sensitive
:
A1
ribociclib
Sensitive: A1 - Approval
ribociclib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
pertuzumab/trastuzumab/hyaluronidase-zzxf
Sensitive: A1 - Approval
pertuzumab / trastuzumab / hyaluronidase-zzxf
Sensitive
:
A1
pertuzumab/trastuzumab/hyaluronidase-zzxf
Sensitive: A1 - Approval
pertuzumab / trastuzumab / hyaluronidase-zzxf
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
abemaciclib
Sensitive: A1 - Approval
abemaciclib
Sensitive
:
A1
abemaciclib
Sensitive: A1 - Approval
abemaciclib
Sensitive
:
A1
PD-L1 expression
Triple Negative Breast Cancer
PD-L1 expression
Triple Negative Breast Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login